Pancreatic Cancer Research

ResearcherBeckman Research InstituteActive in the last 2 years

Michael A. Caligiuri

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4095-3020; OpenAlex author ID A5049192022; NIH RePORTER profile ID 6487056. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
2
Labs led
2
Collaborators
9
Papers, trials and grants by year

2011: 1 grant · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 1 grant

Papers 4

  1. Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer. Co-author DOI 10.1136/jitc-2025-011890↗
  2. Off-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice. Co-author DOI 10.1172/jci179014↗
  3. Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. Co-author DOI 10.1016/j.stem.2024.03.018↗
  4. Off-the-Shelf Prostate Stem Cell Antigen-Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2021.12.281↗

Grants 2

  1. Human natural killer cells: Advancing biology and clinical applications R35CA210087↗
  2. Innate Immunity: Elucidation and Modulation for Cancer Therapy P01CA095426↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jianhua Yu · 3 shared papers, 2022–2025 · strength 0.62
  2. Zhixin Li · 2 shared papers, 2024–2025 · strength 0.45
  3. Zahir Shah · 2 shared papers, 2024–2025 · strength 0.45
  4. Kun‐Yu Teng · 2 shared papers, 2022–2025 · strength 0.37
  5. Li-Shu Wang · 1 shared paper, 2025 · strength 0.24
  6. Laleh Golkar Melstrom · 1 shared paper, 2025 · strength 0.24
  7. Zhenyu Dai · 1 shared paper, 2025 · strength 0.24
  8. Jianhua Yu · 1 shared paper, 2024 · strength 0.20
  9. Zheng Gang Zhu · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.